Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody

A monoclonal antibody medication has been developed by Visterra, Inc. that prevents all strains of influenza type A from infecting host cells. The effectiveness of the product, VIS410, has been demonstrated in mice and clinical trials in people are expected to be started c. 2014.

The results of the mouse study suggests that the product could be an effective prevention and treatment for seasonal and new pandemic strains of influenza.


Summary by Alan Detwiler: Bio at